T. Rowe Price Investment Management, Inc. Cytokinetics Inc Transaction History
T. Rowe Price Investment Management, Inc.
- $162 Billion
- Q4 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Cytokinetics Inc stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 10,752,123 shares of CYTK stock, worth $540 Million. This represents 0.31% of its overall portfolio holdings.
Number of Shares
10,752,123
Previous 9,689,987
10.96%
Holding current value
$540 Million
Previous $512 Million
1.14%
% of portfolio
0.31%
Previous 0.31%
Shares
9 transactions
Others Institutions Holding CYTK
# of Institutions
396Shares Held
122MCall Options Held
3.46MPut Options Held
1.86M-
Black Rock Inc. New York, NY14.7MShares$737 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$599 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.89MShares$396 Million0.07% of portfolio
-
State Street Corp Boston, MA6.17MShares$310 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.84MShares$143 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.73B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...